Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term registry-based follow-up of Gardasil 9 versus Gardasil in women from Protocol V503-001
2023-508683-30-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2008
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine and qHPV vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 5 more (2 arms), sponsored by Merck & Co. Primary endpoint: Combined incidence of HPV 16/18/31/33/45/52/58-related CIN 2/3, AIS, and cervical cancer in Cohort 1. Planned start Mar 2008; status: authorised.
02
Drugs
recombinant human papillomavirus 9-valent vaccineqHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranal cancer
Beyond the preview
Go deeper on 2023-508683-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508683-30-00.